We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Pancreatic Cancer to Be Target of Arizona Research Effort

By LabMedica International staff writers
Posted on 08 Jul 2013
Two US biomedical organizations based in the state of Arizona have agreed to combine their expertise to discover and develop diagnostic markers for detecting and treating cancer.

The partnership comprises Ventana Medical Systems, Inc. More...
(Tucson, AZ, USA), a member of the Roche Group (Basel, Switzerland) and the Translational Genomics Research Institute (Phoenix, AZ, USA). Ventana Medical Systems manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics, while the Translational Genomics Research Institute is a nonprofit research institute that supports and promotes research on neurological disorders, cancer, and diabetes.

The first target is expected to be pancreatic cancer. This disease, which affects more than 213,000 new patients each year worldwide, has the worst survival rate of any cancer. Fewer than 25% of patients survive more than a year after being diagnosed, and less than 6% are still alive after five years.

"The Translational Genomics Research Institute is on the cutting edge of translational research, where investigators discover the genetic components of disease," said Dr. Jeffrey Trent, president and research director of The Translational Genomics Research Institute. "Our goal is to rapidly translate basic research findings into actionable targets. Partnering with Ventana we hope will accelerate our goal to deliver meaningful discoveries to cancer patients today."

"When a patient is faced with cancer, getting an accurate diagnosis quickly is the most important part of their treatment," said Mara G. Aspinall, president and CEO of Ventana. "As the global leader in tissue-based cancer diagnostics, our strength is moving research into the clinic in order to improve the lives of all patients afflicted with cancer. We are thrilled to be able to pursue this with a partner right in our Arizona backyard."

Related Links:
Ventana Medical Systems, Inc.
The Roche Group
The Translational Genomics Research Institute



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.